Position in EXEL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$8,105,728
+$1,722,411 QoQ
Shares Held
148,975
+0.1% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#140
of 756 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vident Advisory, LLC holds $52,891,507 across 43 Biotechnology names. EXEL ranks #1 (15.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
148,975 | $8,105,728 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
28,409 | $6,845,716 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,522 | $6,220,051 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,804 | $4,866,104 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
13,776 | $2,579,967 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
6,151 | $1,944,268 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,518 | $1,661,083 | |
| 8 | CYTK |
Cytokinetics Inc
|
15,898 | $1,354,349 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,105,728 | 148,975 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $6,383,317 | 148,830 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $6,745,479 | 153,901 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $6,228,699 | 150,816 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $7,466,665 | 169,389 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $10,295,620 | 278,863 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $5,190,603 | 155,874 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $3,088,672 | 119,024 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||